CORE Biomedicine
Summary active Updated Jul 29, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
CORE Biomedicine is a biotechnology company pioneering lineage-based precision oncology therapeutics with operations in Boston, Tokyo, and Suzhou 12. The company’s lineage-based approach is designed to identify and target core oncology drivers with precision while expanding the potential patient populations that may benefit from these novel therapies 12. On 2026-07-28, CORE Biomedicine announced a $21 million Series A co-led by UTokyo Innovation Platform and Elikon Venture, with participation from InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture Capital, Vision Incubate, and Root Venture Partners 12. Alongside the financing, the company’s wholly owned subsidiary CORE Biomedicine Japan received a grant through the Strengthening Program for Pharmaceutical Startup Ecosystem run by the Japan Agency for Medical Research and Development (AMED) 12.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-28 | Series A | $21M | UTokyo Innovation Platform, Elikon Venture | InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture Capital, Vision Incubate, Root Venture Partners 12 |
What Investors Say
No independently sourced investor commentary quoted at press time.
What Founders Say
No independently sourced founder quotes located at press time.
Sources
-
BioSpace, “CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics,” July 28, 2026. Accessed July 2026. https://www.biospace.com/press-releases/core-biomedicine-secures-21-million-series-a-venture-financing-and-receives-amed-grant-award-to-advance-novel-cancer-therapeutics↩↩↩↩↩
-
PR Newswire, “CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics,” July 28, 2026. Accessed July 2026. https://www.prnewswire.com/news-releases/core-biomedicine-secures-21-million-series-a-venture-financing-and-receives-amed-grant-award-to-advance-novel-cancer-therapeutics-302836054.html↩↩↩↩↩